Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab

類似資料

• Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
  著者:: Kalabus, J, 等
  出版事項: (2015)
• Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
  著者:: Kuemmerle-Deschner, J, 等
  出版事項: (2015)
• PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
  著者:: Hofer, F, 等
  出版事項: (2013)
• Canakinumab treat-to target strategies increase complete response rate in CAPS
  著者:: Kuemmerle-Deschner, J, 等
  出版事項: (2015)
• Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
  著者:: Brogan, Paul A., 等
  出版事項: (2019)